Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

S Shimony, M Stahl, RM Stone - American Journal of …, 2023 - Wiley Online Library
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

ST Diepstraten, MA Anderson, PE Czabotar… - Nature Reviews …, 2022 - nature.com
Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

Acute myeloid leukaemia

CD DiNardo, HP Erba, SD Freeman, AH Wei - The Lancet, 2023 - thelancet.com
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Updates on targeted therapies for acute myeloid leukaemia

S Kayser, MJ Levis - British journal of haematology, 2022 - Wiley Online Library
In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Venetoclax combined with azacitidine and homoharringtonine in relapsed/refractory AML: a multicenter, phase 2 trial

H Jin, Y Zhang, S Yu, X Du, N Xu, R Shao, D Lin… - Journal of Hematology & …, 2023 - Springer
Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

[HTML][HTML] Venetoclax resistance: mechanistic insights and future strategies

F Ong, K Kim, MY Konopleva - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Current status and future perspectives in targeted therapy of NPM1-mutated AML

R Ranieri, G Pianigiani, S Sciabolacci, VM Perriello… - Leukemia, 2022 - nature.com
Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

CA Lachowiez, N Long, J Saultz, A Gandhi… - Blood …, 2023 - ashpublications.org
Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

Venetoclax plus 3+ 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial

H Wang, L Mao, M Yang, P Qian, H Lu… - The Lancet …, 2022 - thelancet.com
Background Adults with acute myeloid leukaemia have unsatisfactory clinical outcomes and
rates of complete remission. Venetoclax combined with azacytidine or low-dose cytarabine …

Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia

MM Naldini, G Casirati, M Barcella… - Nature …, 2023 - nature.com
Acute myeloid leukemia may be characterized by a fraction of leukemia stem cells (LSCs)
that sustain disease propagation eventually leading to relapse. Yet, the contribution of LSCs …